Joaquina Baranda

Dr. Joaquina Baranda

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAnwaar Saeed
Anwaar Saeed
RPRobin Park
Robin Park
HPHarsh Pathak
Harsh Pathak
AAAyah N. Al-Bzour
Ayah N. Al-Bzour
JDJunqiang Dai
Junqiang Dai
ASAzhar Saeed
Azhar Saeed
CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results. 29 patients were evaluable. 100% had confirmed pMMR/MSS tumors. Primary endpoint was met with ORR of 27.6% (95% CI 12.7-47.2%). Secondary endpoints of 4-month PFS rate was 44.83% (95% CI 26.5-64.3%); and median OS was 9.1 months (95% CI 5.8-20.2). Grade≥3 TRAE occurred in 39%. In post-hoc analysis of patients with RAS wild type tumors, ORR was 50% and median PFS and OS were 6.3 and 21.5 months respectively. Exploratory spatial transcriptomic profiling of pretreatment tumors showed upregulation of VEGF and MET signaling, increased extracellular matrix activity and preexisting anti-tumor immune responses coexisting with immune suppressive features like T cell migration barriers in responders versus non-responders. Cabozantinib plus durvalumab demonstrated anti-tumor activity, manageable toxicity, and have led to the activation of the phase III STELLAR-303 trial.

1 April 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
Prasad DandawatePrasad Dandawate
Prasad Dandawate
GKGaurav Kaushik
Gaurav Kaushik
CGChandrayee Ghosh
Chandrayee Ghosh
DSDavid Standing
David Standing
ASAfreen Asif Ali Sayed
Afreen Asif Ali Sayed
SAShrikant Anant
Shrikant Anant

13 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
IFIan M. Freed
Ian M. Freed
AKAnup Kasi
Anup Kasi
OFOluwadamilola Fateru
Oluwadamilola Fateru
MHMengjia Hu
Mengjia Hu
PGPhasin Gonzalez
Phasin Gonzalez
SSSteven Soper
Steven Soper
There is a high clinical unmet need to improve outcomes for pancreatic ductal adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers that can track response to treatment more efficiently than imaging. We report an innovative approach that will generate renewed interest in using circulating tumor cells (CTCs) to monitor treatment efficacy, which, in this case, used PDAC patients receiving an exploratory new therapy, poly ADP-ribose polymerase inhibitor (PARPi)—niraparib—as a case study. CTCs were enumerated from whole blood using a microfluidic approach that affinity captures epithelial and mesenchymal CTCs using anti-EpCAM and anti-FAPα monoclonal antibodies, respectively. These antibodies were poised on the surface of two separate microfluidic devices to discretely capture each subpopulation for interrogation. The isolated CTCs were enumerated using immunophenotyping to produce a numerical ratio consisting of the number of mesenchymal to epithelial CTCs (denoted “Φ”), which was used as an indicator of response to therapy, as determined using computed tomography (CT). A decreasing value of Φ during treatment was indicative of tumor response to the PARPi and was observed in 88% of the enrolled patients (n = 31). Changes in Φ during longitudinal testing were a better predictor of treatment response than the current standard CA19-9. We were able to differentiate between responders and non-responders using ΔΦ (p = 0.0093) with higher confidence than CA19-9 (p = 0.033). For CA19-9 non-producers, ΔΦ correctly predicted the outcome in 72% of the PDAC patients. Sequencing of the gDNA extracted from affinity-selected CTC subpopulations provided information that could be used for patient enrollment into the clinical trial based on their tumor mutational status in DNA repair genes.

13 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JAJessica Allen
Jessica Allen
CCColin Cernik
Colin Cernik
SBSuhaib Bajwa
Suhaib Bajwa
RARaed Al-Rajabi
Raed Al-Rajabi
ASAnwaar Saeed
Anwaar Saeed
AKAnup Kasi
Anup Kasi
We examined the relationship between the daily rate of change of cancer antigen 19-9 (CA19-9) over the first 90 days of treatment (DRC90) and the pretreatment levels of neutrophils, lymphocytes, and platelets with the overall survival (OS) and progression-free survival (PFS) in patients with stage IV pancreatic ductal adenocarcinoma (PDA) who received chemotherapy. We retrospectively evaluated 102 locally advanced and metastatic PDA patients treated at the University of Kansas Cancer Center (KUCC) between January 2011 and September 2019. We compared the ratio of the pretreatment absolute neutrophil count to the pretreatment absolute lymphocyte count (NLR) and the ratio between the pretreatment platelet count to the pretreatment absolute lymphocyte count (PLR) with the OS and PFS. We compared the DRC90 to the OS and PFS. The ratios were analyzed using the log-rank trend test using the mean of the NLR, PLR, and DRC90 as the threshold for two groups within each variable. Patients with ≥mean NLR (4.6 K/µL) had a significantly lower OS (p = 0.0444) and PFS (p = 0.0483) compared with patients below the mean. Patients with PLR ≥ mean (3.9 K/µL) did not have a significantly different OS (p = 0.507) or PFS (p = 0.643) compared with patients below the mean. Patients with DRC90 ≥ mean (−1%) did not have a significantly different OS (p = 0.342) or PFS (p = 0.313) compared with patients below the mean. Patients with NLR ≥ mean (4.6 K/µL) had a significantly lower OS and PFS compared with patients with NLR below the mean. This implies the possibility of NLR as a prognostic marker in PDA that could guide treatment approaches but still requires validation in a larger cohort.

15 July 2025 in European Journal of Cancer
Verified
Journal Article
Open access
KMKei Muro
Kei Muro
TFTrevor Feinstein
Trevor Feinstein
JBJoaquina Baranda
Joaquina Baranda
IBIoana Bonta
Ioana Bonta
NYNoriko Yanagitani
Noriko Yanagitani
TPTejas Patil
Tejas Patil
Enfortumab vedotin (EV), a novel antibody-drug conjugate directed against Nectin-4, was explored in patients with non-small cell lung cancer (NSCLC) in cohorts 3 and 4 of the open-label, multicohort, Phase 2 EV-202 study (NCT04225117). Patients with squamous and non-squamous NSCLC previously treated with platinum and PD-1/L1 inhibitors received EV 1.25 mg/kg intravenously on days 1, 8, and 15 of 28-day cycles. A Bayesian optimal design for Phase 2 was used, with interim analysis (IA) conducted when 20 patients were response-evaluable by investigator assessment. Primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included duration of response, disease control rate, progression-free survival (PFS), overall survival (OS), and safety. Of 40 patients, ≥ 7 and ≥ 10 responders were needed at final analysis to claim promising antitumor activity in squamous and non-squamous cohorts, respectively. Sixty-six patients were enrolled: 23 in squamous, 43 in the non-squamous cohort. One patient in the squamous cohort achieved a response at IA; thus, enrollment was closed. In the non-squamous cohort, 6 patients achieved partial response (ORR [95 % CI], 14.0 % [5.3-27.9 %]) at final analysis; median (95 % CI) PFS and OS were 4.1 (2.8-5.7) and 10.5 (8.1-13.1) months, respectively. Most common treatment-related adverse events (≥30 % patients) in the non-squamous cohort were rash maculopapular and peripheral sensory neuropathy (37.2 % each); pruritus (34.9 %); and alopecia (32.6 %). Although the predefined efficacy thresholds were not met in either cohort, the antitumor activity of EV in non-squamous NSCLC may support the option for further investigation in this population.

19 June 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
JBJoaquina Baranda
Joaquina Baranda
DRDebbie Robbrecht
Debbie Robbrecht
RSRyan Sullivan
Ryan Sullivan
BDBernard Doger
Bernard Doger
ASArmando Santoro
Armando Santoro
FHF. Stephen Hodi
F. Stephen Hodi
SAR439459 (SAR'459), a “second‐generation” human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty‐eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness‐of‐fit plots and adequately described the observed data by a two‐compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment‐emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.